Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR84 | Q9NQS5 | 1/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 7/20 | 0.34 |
| ▸ | PSEN2 | P49810 | 7/20 | 0.34 |
| ▸ | APH1B | Q8WW43 | 7/20 | 0.34 |
| ▸ | NCSTN | Q92542 | 7/20 | 0.34 |
| ▸ | APH1A | Q96BI3 | 7/20 | 0.34 |
| ▸ | PSENEN | Q9NZ42 | 7/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24608829 | 1.00 | GPR84 (0.38) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21239934 | 0.98 | GPR84 (0.36) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL23489973 | 0.86 | PSEN1 (0.34) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22758634 | 0.85 | NR1I2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL18948474 | 0.85 | NR1I2 (0.33) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL22926088 | 0.81 | ALDH1A1 (0.39) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL24659233 | 0.78 | GPR84 (0.35) | GPR84PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL21695392 | 0.72 | ALOX5 (0.36) | GPR84MEN1KMT2ANPSR1OPRM1 | |
| SCHEMBL25018102 | 0.72 | LMNA (0.36) | OPRM1 | |
| SCHEMBL22961504 | 0.71 | LMNA (0.35) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | INCYTE CORPORATION (US) | 2021-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975088-B2 | Imidazo[2,1-f][1,2,4]triazine compounds as pi3k-y inhibitors | PIK3R5, PIK3CD, PIK3CA | GPR84 1349/4885PSEN1 1519/4885PSEN2 1641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.